Search results
Left Atrial Appendage Closure Devices for Stroke Prevention in Patients with Non-Valvular AF
Author(s):
Daniel A McBride
,
Timothy M Markman
,
Jackson J Liang
,
et al
Added:
3 years ago
Article
Author(s):
David Berg
Added:
1 year ago
ESC Congress 22 — Dr David Berg (Brigham and Women's Hospital, US) shares key results from the TIMI Study Group's COVID-PACT trial (NCT04409834).
This multicenter, randomized-controlled trial assessed efficacy and safety of full-dose vs. standard prophylactic dose anticoagulation and of antiplatelet vs. no antiplatelet therapy for prevention of venous and arterial thrombotic events. The study…
View more
Author(s):
Milind Y Desai
Added:
1 year ago
In this short summary interview, Dr Milind Y Desai (Cleveland Clinic, US) shares the findings from the VALOR-HCM trial (MyoKardia) (NCT04349072).
This randomised, multicentre study was designed to assess the effect of mavacamten treatment on reducing the number of septal reduction therapy (SRT) procedures performed in subjects with symptomatic obstructive hypertrophic cardiomyopathy.
Discussion…
View more
Author(s):
Praveen Rao
,
Olusegun Olusesi
,
Mitchell Faddis
Added:
3 years ago
It is presumed that the pathogenesis of stroke in atrial fibrillation (AF) patients is due to embolization of thrombus from the left atrium. Within the left atrium, the left atrial appendage is the predominant site of thrombus formation. In a study of 233 patients with new onset AF of greater than 48 hours in duration who were not anticoagulated, left atrial appendage thrombus was present in 15 %…
View more
Transesophageal Echocardiography
Author(s):
Bijoy K Khandheria
Added:
3 years ago
Article
Transesophageal Echocardiography
Author(s):
Bijoy K Khandheria
Added:
3 years ago
Article
Author(s):
Naga Venkata Pothineni
,
Srikanth Vallurupalli
Added:
3 years ago
Atrial fibrillation (AF) is the most common clinically relevant supraventricular arrhythmia. AF is a leading risk factor for stroke and accounts for about one-third of all ischemic cerebrovascular events.1 The last two decades have witnessed a paradigm shift in the management of AF with the development of catheter ablation and improvements in anticoagulant therapies. In this review, we discuss…
View more
Author(s):
Gerald V Naccarelli
,
Deborah L Wolbrette
,
Mazhar Khan
,
et al
Added:
3 years ago
Abstract
Prospective trials have demonstrated that flecainide, propafenone, quinidine, and sotalol are equally effective in preventing recurrences of atrial fibrillation (AF). A new twice-a-day formulation of propafenone has been demonstrated to have efficacy that is higher than the short-acting form of the drug. Dofetilide, although useful for terminating and preventing recurrence of persistent…
View more